Cardiol Therapeutics Free Cash Flow (FCF) History (CRDL)
Cardiol Therapeutics reported −$23.9M in free cash flow for fiscal 2025, an increase of $1.2M from the previous fiscal year.
View full Cardiol Therapeutics company overviewCardiol Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$23.9M | $1.2M | — | — |
| 2024 | 2024-12-31 | −$25.1M | $162,596 | — | — |
| 2023 | 2023-12-31 | −$25.2M | $2.1M | — | — |
| 2022 | 2022-12-31 | −$27.3M | −$3.7M | — | — |
| 2021 | 2021-12-31 | −$23.6M | −$14.4M | — | −29904.22% |
| 2020 | 2020-12-31 | −$9.2M | — | — | — |
Cardiol Therapeutics quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$4.4M | $174,805 | — | — |
| Q1 2026 | 2026-03-31 | −$7.6M | −$399,510 | — | — |
| Q4 2025 | 2025-12-31 | −$5.2M | — | — | — |
| Q3 2025 | 2025-09-30 | −$6.9M | — | — | — |
| Q2 2025 | 2025-06-30 | −$4.6M | — | — | — |
| Q1 2025 | 2025-03-31 | −$7.2M | — | — | — |
Cardiol Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$9.2M to −$23.9M, a net decrease of $14.7M. Cardiol Therapeutics's latest reported quarter, Q2 2026, generated −$4.4M in free cash flow, an increase of $174,805 year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Cardiol Therapeutics source filings ↗